2[1]Sasaki T,Maeda Y,Kobayashi T,et al.Standard chemotherapy for gastrointestinal malignancies based on evidence.Jap J Cancer Chemother,2000,27 (20):166
3[4]Jin M,Shen L,Hu B,et al.Mature data on capecitabine (X) + fractionated cisplatin (P) as first-line therapy in patients (pts) with advanced gastric carcinoma (AGC).Proc Am Soc Clin Oncol,2006,24:196S
4[5]Kang Y,Kang WK,Shin DB,et al.Randomized phase Ⅲtrial of capecitabine/cisplatin (XP) vs continuous infusion of 5 -FU/cisplatin (FP) as first-line therapy in patients (pts) with advanced gastric cancer (AGC):Efficacy and safety results.Proc Am Soc Clin Oncol,2006,24:183S
5[6]Shitara K,Sakata Y,Kudou T,et al.Gastric Cancer:S -1 monotherapy and its progress.Jpn J Cancer Chemother,2006,33 (Suppl I):43
6[7]Ajani JA,Fodor MB,Tjulandin SA,et al.Phase Ⅱ multiinstitutional randomized trial of docetaxel plus cisplatin with or without fluorouracil in patients with untreated,advanced gastric or gastroesophageal adenocarcinoma.J Clin Oncol,2005,23 (24):5660
7[9]Cunningham D,Rao S,Starling N,et al.Randomised multicentie phase Ⅲ study comparing capecitabine with fluorouracil and oxaliplatin with cisplatin in patientswith advanced oesophagogastric cancer:The REAL 2 trial.Proc Am Soc Clin Oncol,2006,24:182S
8[10]Park Y,Lee J,Ryoo B,et al.Aphase Ⅱ study of capecitabine plus oxaliplatin (XELOX) as first-line therapy for patients with advanced gastric cancer.Proc Am Soc Clin Oncol,2006,24:197S
9[11]Pozzo C,Bugat R,Peschel C,et al.Irinotecan in combination with CDDP or 5-FU and folinic acid is active in patients with advanced gastric or gastrooesophagealjunction adenocarcin oma:Final results of a randomized phase Ⅱ study.Proc Am Soc Clin Oncol,2000,20:531
10[12]Bouche O,Raoul J,Giovanini M,et al.Randomized phase Ⅱ trial of LV5FU2,LV5FU2-cisplatinum or LV5FU2-irinotecan in patients (pts) with metastatic gastric or cardial adenocarcinoma (MGA):Final results of study FFCD9803,Proc Am Soc Clin Oncol,2003,21,1033
